Company Overview - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team operates from key finance and investing hubs including London, New York, Toronto, Vancouver, Sydney, and Perth [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The content includes insights across various sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Utilization - Proactive is a forward-looking company that adopts technology enthusiastically to enhance workflows [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

Core Insights - BioVie Inc. announced the acceptance of an abstract for its SUNRISE-PD study on bezisterim (NE3107) for treating Parkinson's Disease at the AD/PD 2026 conference [1][2] Group 1: Study and Results - The abstract titled "Demographics and Baseline Characteristics of Participants in a Study of Bezisterim (NE3107) in Early Parkinson's Disease (SUNRISE-PD)" summarizes initial data from the study, which will be presented as a poster [2] - Topline results from the SUNRISE-PD study are expected in mid-2026, following the enrollment of 60 patients to evaluate bezisterim's efficacy in improving motor and non-motor symptoms in untreated Parkinson's patients [4] Group 2: Drug Mechanism and Applications - Bezisterim (NE3107) is an oral drug that crosses the blood-brain barrier, aiming to reduce inflammation and improve insulin sensitivity without immune suppression, showing potential for various neurological conditions including Parkinson's, Long COVID, and Alzheimer's [3][7] - In previous Phase 2 studies for Parkinson's, patients taking bezisterim with levodopa exhibited better motor control and fewer symptoms compared to those on levodopa alone, with minimal side effects reported [4] Group 3: Other Clinical Trials - The ADDRESS-LC trial is currently enrolling about 200 patients to assess bezisterim's ability to alleviate neurological symptoms associated with Long COVID, with topline data also expected in mid-2026 [5] - BioVie has conducted Phase 2 and Phase 3 trials for Alzheimer's disease, with early results indicating improvements in cognition and biomarkers, warranting further investigation [6] Group 4: Company Overview - BioVie Inc. is a clinical-stage biopharmaceutical company focused on therapies for neurological disorders and advanced liver disease, with bezisterim targeting neuroinflammation and insulin resistance [7] - The company is also advancing BIV201, a treatment for liver disease that has received FDA Orphan and Fast Track designations, and plans to conduct a Phase 3 trial for patients with cirrhosis and ascites [8]

Core Viewpoint - BioVie is actively engaging with investors through a presentation led by its President and CEO, Cuong Do, highlighting the company's strategic direction and future prospects [1]. Company Overview - BioVie trades on NASDAQ under the ticker symbol "BioVie" [1]. - The event is organized by Redchip Companies, indicating a focus on investor relations and market engagement [1]. Future Outlook - The presentation may include forward-looking statements regarding financial and operational results, reflecting management's expectations and strategic goals [1]. - The company acknowledges that these forward-looking statements involve inherent risks and uncertainties, which are typical in the biotech sector [1].

Core Viewpoint - Eoin Tonge has been appointed as the permanent CEO of Primark, succeeding his role as interim CEO, during a period of sluggish sales for the retailer [1] Company Summary - Eoin Tonge has been serving as the interim CEO of Primark since last year [1] - The company is currently facing challenges with sluggish sales [1]

Summary of BioVie Conference Call Company Overview - **Company**: BioVie Inc. (Ticker: BIVI) - **Focus**: Development of drug candidates for neurological and liver diseases, specifically targeting Parkinson's disease, long COVID, and ascites Key Drug Candidates Bezisterim (formerly NE3107) - **Mechanism**: Modulates inflammation by blocking TNF-alpha production, which is linked to various diseases including Parkinson's and Alzheimer's [3][6] - **Clinical Trials**: - **Parkinson's Trial**: Fully enrolled, top-line data expected in Q2 2026 [4][5] - **Long COVID Trial**: Rapid enrollment, top-line data expected by August 2026 [5][21] - **Clinical Findings**: - In Parkinson's patients, bezisterim showed improvements in muscle control and reduced insulin resistance [11][15] - Combination with Levodopa demonstrated a synergistic effect, improving motor control and reducing dyskinesia [16][18] - Neuroprotective properties observed, with treated subjects retaining more neurons [17] - **Market Potential**: Estimated annual sales opportunity of $3 billion to $5 billion in the U.S. for Parkinson's treatment [31] BIV201 - **Indication**: Treatment for ascites, a severe liver disease with over 50% mortality within a year [22][24] - **Clinical Trials**: - Phase 2 trials showed over 50% reduction in ascites fluid buildup [26] - Fast track and orphan designation received from the FDA, with plans for a Phase 3 trial [27][28] - **Market Potential**: Estimated annual sales of $2 billion in the U.S. [55] Industry Context - **Long COVID**: Affects approximately 17 million Americans, with no approved treatments available [20][32] - **Market Need**: Significant unmet medical need for both long COVID and ascites, highlighting the potential for bezisterim and BIV201 to fill these gaps [20][24] Financial and Strategic Considerations - **Funding Challenges**: Difficulty in raising necessary funds for trials, with discussions ongoing for potential partnerships [33][34] - **Regulatory Path**: Plans to seek accelerated approval or emergency use authorization for long COVID treatment based on trial results [31][48] - **Investor Sentiment**: Current market conditions have led to a depressed stock price, with hopes that positive trial results will improve investor interest [36][37] Conclusion - BioVie is positioned with two promising drug candidates, bezisterim and BIV201, targeting significant health issues with substantial market potential. Upcoming clinical trial results are critical for the company's future and investor confidence.

Core Insights - BioVie Inc. is hosting a webinar on March 4, 2026, to discuss its investigational drug candidate bezisterim (NE3107) and its orphan drug candidate BIV201 [1][2][3] Group 1: Drug Development - Bezisterim (NE3107) is a first-in-class, orally available small molecule targeting inflammation and insulin resistance, which are key drivers of Alzheimer's, Parkinson's, and Long COVID, showing promising results in improving cognition, motor function, and reducing neuroinflammation [2][6] - BIV201 is a continuous infusion treatment of terlipressin for patients with cirrhosis and ascites, which has received FDA Orphan and Fast Track designations, and is set to enter a Phase 3 trial [3][7] Group 2: Market Potential - BioVie is positioned to create significant value with multiple clinical programs advancing into late-stage development, supported by strong safety data and multi-billion-dollar market opportunities [3] - The company aims to address life-threatening complications in liver disease with no FDA-approved therapies currently available [3][7]

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team covers medium and small-cap markets, as well as blue-chip companies, commodities, and broader investment stories [3] - Proactive's content includes insights across various sectors such as biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] Group 2 - Proactive is committed to adopting technology to enhance workflows and content production [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

Core Viewpoint - BioVie Inc. announced the acceptance of two abstracts for its lead candidate bezisterim (NE3107) at the 2026 American College of Psychiatrists annual meeting, focusing on Alzheimer's Disease and Long COVID [1][2]. Group 1: Bezisterim Overview - Bezisterim (NE3107) is an oral drug that crosses the blood-brain barrier, aiming to reduce inflammation and improve insulin sensitivity without immune suppression and with low drug-drug interaction risk [3]. - The drug targets neuroinflammation pathways (ERK, NFκB, TNF-α) and has potential applications in Parkinson's disease, Long COVID, and Alzheimer's disease [3]. Group 2: Clinical Trials and Results - In Parkinson's disease, a completed Phase 2 study indicated that patients taking bezisterim with levodopa experienced better motor control and fewer morning symptoms compared to those on levodopa alone, with minimal side effects [4]. - The SUNRISE-PD trial is currently enrolling 60 patients to assess bezisterim's efficacy in improving symptoms for untreated Parkinson's patients, with topline results expected in mid-2026 [4]. - The ADDRESS-LC trial is enrolling around 200 patients to evaluate bezisterim's ability to alleviate neurological symptoms associated with Long COVID, with topline data anticipated in mid-2026 [5]. - In Alzheimer's disease, both Phase 2 and Phase 3 trials have been conducted, showing early results that suggest cognitive improvements and biomarker support for further trials [6]. Group 3: Company Background - BioVie Inc. is a clinical-stage biopharmaceutical company focused on therapies for neurological disorders and advanced liver disease, with bezisterim targeting neuroinflammation and insulin resistance [7]. - The company is also advancing BIV201, a treatment for liver disease that has received FDA Orphan and Fast Track designations, and plans to conduct a Phase 3 trial for its efficacy in patients with cirrhosis and ascites [8].

Core Insights - BioVie Inc is focusing on addressing the root causes of neurodegeneration, particularly in Parkinson's disease, rather than just treating symptoms [1][4][12] Company Overview - BioVie Inc is a clinical-stage biopharmaceutical company with a market capitalization in the tens of millions [1] - The company is advancing bezisterim (NE3107), an oral small-molecule drug aimed at blocking TNF alpha mediated inflammation and reversing insulin resistance [2] Parkinson's Disease Focus - Parkinson's disease affects approximately one million people in the U.S., with prevalence expected to rise as the population ages [3] - Current treatments, primarily Levodopa, do not slow neurodegeneration and can lead to involuntary movements [3] - BioVie posits that Parkinson's symptoms arise from low dopamine levels and chronic inflammation due to insulin resistance [4] Clinical Trials and Data - BioVie has completed enrollment in the SUNRISE-PD trial, evaluating bezisterim in 60 early-stage Parkinson's patients not yet on levodopa therapy [6] - The trial aims to determine if bezisterim can delay motor decline, differentiating it from existing treatments [6] - Topline data from the SUNRISE-PD trial is expected in April or May 2026, marking a significant catalyst for the company [7] Broader Implications of Bezisterim - Beyond Parkinson's, bezisterim is also being studied for long COVID and Alzheimer's disease, where chronic inflammation plays a role [8] - A 200-patient trial for long COVID is underway, supported by a $13 million non-dilutive grant [8] Additional Clinical Asset - BioVie is also advancing BIV201, targeting ascites associated with late-stage liver disease, with a Phase 2 trial showing over 50% reduction in fluid buildup [9] - The program has received FDA clearance to proceed directly into a Phase 3 study under orphan and fast-track designations [9] Market Position and Investment Outlook - Despite a broad clinical portfolio, BioVie’s valuation remains modest, attributed to market skepticism towards early-stage biotech [10] - The company presents a high-risk, high-reward investment opportunity with multiple catalysts expected in the next 12 to 18 months [11] - 2026 is anticipated to be a significant year for the company, with potential for substantial market impact if clinical data supports its hypotheses [11][12]

Financial Performance - The net loss for the three months ended December 31, 2025, was approximately $6.1 million, a decrease from the net loss of approximately $7.1 million for the same period in 2024, reflecting a reduction of $1.0 million [109]. - The net loss for the six months ended December 31, 2025, was approximately $11.2 million, comparable to the net loss of approximately $11.3 million for the same period in 2024 [115]. - For the six months ended December 31, 2025, the Company reported total revenue of approximately $4.9 million, an increase of $818,000 compared to $4.1 million for the same period in 2024 [119]. Operating Expenses - Total operating expenses for the three months ended December 31, 2025, were approximately $6.3 million, down from $7.3 million in 2024, indicating a decrease of approximately $1.0 million [110]. - Total operating expenses for the six months ended December 31, 2025, were approximately $11.5 million, slightly up from $11.4 million in 2024 [116]. - General and administrative expenses decreased to approximately $4.2 million for the six months ended December 31, 2025, down from $4.6 million in 2024, primarily due to reductions in stock-based compensation and consultancy fees [120]. - Legal fee expenses increased by approximately $546,000, primarily related to class action litigation [120]. Research and Development - Research and Development (R&D) expenses were approximately $4.3 million for the three months ended December 31, 2025, compared to $4.7 million in 2024, a decrease of approximately $435,000 attributed to reduced expenses in Long COVID studies [111]. - R&D expenses for the six months ended December 31, 2025, were approximately $7.2 million, an increase of approximately $511,000 from $6.7 million in 2024, driven by increased study costs [117]. - The increase in clinical study costs of approximately $818,000 was primarily due to the Sunrise PD Phase 2 study, which cost approximately $2.3 million [118]. - The Sunrise PD Phase 2 study incurred costs of approximately $2.6 million for the three months ended December 31, 2025, an increase of $1.5 million from $1.2 million in 2024 [112]. - Bezisterim (NE3107) is being tested for its potential to treat Alzheimer's disease, with significant data analysis ongoing from a Phase 3 clinical trial [105]. Funding and Financial Position - The Company received a clinical trial grant of $13.1 million from the U.S. Department of Defense for the Long COVID program, which commenced in May 2025 [101]. - The Company raised approximately $10.5 million in net proceeds from a public offering that closed on August 11, 2025, selling 5,620,000 units at $2.00 per unit [125]. - As of December 31, 2025, the Company had working capital of approximately $18.8 million and cash and cash equivalents totaling approximately $20.5 million [122]. - The Company has an accumulated deficit of approximately $363.3 million as of December 31, 2025 [122]. - The Company faces substantial doubt regarding its ability to continue as a going concern due to uncertainties in obtaining sufficient financing [124]. Accounting Policies - There were no significant changes to the Company's critical accounting policies as identified in the Annual Report Form 10-K for the fiscal year ended June 30, 2025 [126]. Other Income - Other income increased to approximately $390,000 for the six months ended December 31, 2025, compared to $150,000 in 2024, driven by a reduction in interest expense of approximately $315,000 [121]. Revenue Generation - The Company has not generated any revenue and does not expect to do so in the foreseeable future, relying on ongoing development and commercialization efforts for future operations [123].